- Assessment of therapies across a range of animal models, with careful safety and pharmacokinetic studies, is vital before clinical translation.
- Clinical neuroprotection trials in neonates with NE need careful planning, with adequate power and pharmacokinetic information built into the protocols.
- Determination of optimal dose and timing of each agent will be important as we move into the era of therapeutic cocktails for optimizing outcomes.
- The use of MRI and sequences such as MRS as a surrogate outcome measure will speed up the assessment of efficacy of potential therapies and thus accelerate clinical translation.
To view the full text and an associated presentation, become a NBS member here